ARS Pharmaceuticals, Inc. logo SPRY - ARS Pharmaceuticals, Inc.

Price: -- -- | CONSENSUS: Hold DETAILS
STRONG
BUY 1
BUY 3
HOLD 6
SELL 0
STRONG
SELL 0
| PRICE TARGET: $25.50 DETAILS
HIGH: $26.00
LOW: $25.00
MEDIAN: $25.50
CONSENSUS: $25.50
UPSIDE: 221.16%

Stock News

ARS Pharmaceuticals: Still A Buy As Neffy Access Improves

ARS Pharmaceuticals: Still A Buy As Neffy Access Improves

ARS Pharmaceuticals is now focused on scaling Neffy. This is their needle-free epinephrine spray for severe allergic reactions, and it's also core to my bull case on SPRY. Recently, we've seen SPRY double down on CVS Caremark, Medicaid, retail affordability, and a larger sales force to improve Neffy's access by 2H2026. Neffy is already generating commercial revenue, and the next test for my bull case is whether repeat sales grow as access improves.

May 20, 2026 01:27 AM • seekingalpha.com
ARS Pharmaceuticals Strengthens Leadership Team with Appointment of Industry Veteran Donn Casale as President

ARS Pharmaceuticals Strengthens Leadership Team with Appointment of Industry Veteran Donn Casale as President

SAN DIEGO, May 13, 2026 (GLOBE NEWSWIRE) -- ARS Pharmaceuticals, Inc. (Nasdaq: SPRY), a biopharmaceutical company dedicated to empowering patients and their caregivers to better protect against severe allergic reactions that can lead to anaphylaxis, today announced the appointment of Donn Casale as President, effective June 1, 2026. Richard Lowenthal will continue to lead ARS Pharma as Chief Executive Officer.

May 13, 2026 04:00 AM • globenewswire.com
ARS Pharmaceuticals Announces Conference Call and Webcast for its First Quarter 2026 Financial Results

ARS Pharmaceuticals Announces Conference Call and Webcast for its First Quarter 2026 Financial Results

SAN DIEGO, May 07, 2026 (GLOBE NEWSWIRE) -- ARS Pharmaceuticals, Inc. (Nasdaq: SPRY), a biopharmaceutical company dedicated to empowering at-risk patients and their caregivers to better protect patients from allergic reactions that could lead to anaphylaxis, today announced the company will host a conference call and webcast on Friday, May 15, 2026, at 5:30 a.m. PT / 8:30 a.m. ET to discuss its first quarter 2026 financial results and business highlights.

May 07, 2026 04:00 AM • globenewswire.com
ARS Pharmaceuticals: Neffy's Slow Launch, No Guidance For 2026 Keep Me On Sidelines

ARS Pharmaceuticals: Neffy's Slow Launch, No Guidance For 2026 Keep Me On Sidelines

ARS Pharmaceuticals, Inc. maintains a Hold rating as neffy's commercial uptake remains slow despite FDA approval and a robust marketing push. SPRY reported 2025 revenues of $84.3m, a net loss of $171.3m, and plans to sustain high SG&A spending to accelerate U.S. market share. Management offers no 2026 revenue guidance, raising concerns about breakeven prospects and ongoing competition from established and emerging epinephrine products.

Mar 11, 2026 08:38 AM • seekingalpha.com
ARS Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results and Updates on neffy® (epinephrine nasal spray) Commercialization

ARS Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results and Updates on neffy® (epinephrine nasal spray) Commercialization

neffy delivers $72.2 million of U.S. net product revenue in first full year Intranasal epinephrine platform advances with Phase 2b CSU data expected mid-2026 Strong balance sheet of $245.0 million in cash, cash equivalents and short-term investments supports operating plan through anticipated cash-flow break-even    Conference call to be held today, March 9, 2026, at 5:30 a.m. PT / 8:30 a.m.

Mar 09, 2026 02:00 AM • globenewswire.com
ARS Pharmaceuticals Announces Conference Call and Webcast for its Fourth Quarter and Full Year 2025 Financial Results and Participation at Upcoming Conferences

ARS Pharmaceuticals Announces Conference Call and Webcast for its Fourth Quarter and Full Year 2025 Financial Results and Participation at Upcoming Conferences

SAN DIEGO, Feb. 23, 2026 (GLOBE NEWSWIRE) -- ARS Pharmaceuticals, Inc. (Nasdaq: SPRY), a biopharmaceutical company dedicated to empowering at-risk patients and their caregivers to better protect patients from allergic reactions that could lead to anaphylaxis, today announced the company will host a conference call and webcast on Monday, March 9, 2026 at 5:30 a.m. PT / 8:30 a.m.

Feb 23, 2026 03:00 AM • globenewswire.com

Price Targets